A Phase 1/1b study of ALTA2618 in AKT1 E17K-mutant solid tumors

Active, Not Recruiting Phase 1 NCT06533059

Study Description

A study to evaluate the safety, tolerability, and efficacy of the investigational drug ALTA2618 in adults with advanced solid tumors harboring the AKT1 E17K mutation

Study Details

Registry ID:
NCT06533059
Conditions:
Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Phase:
Phase 1
Target Enrollment:
110 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (41 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →